Medulloblastoma – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032

 

Medulloblastoma is the most common type of malignant brain tumour in children. It is an embryonal lesion that is thought to develop from progenitor cell populations present during early brain development. Medulloblastoma accounts for about 20% of all paediatric brain tumours and 63% of intracranial embryonal tumours. Hereditary cancer predisposition syndromes are primary risk factors for the development of medulloblastoma. Germline mutations in WNT signalling pathway genes, such as APC mutations, which occur in Turcot syndrome, can predispose to WNT medulloblastoma. WNT subgroup medulloblastoma accounts for approximately 10% of all medulloblastoma. Medulloblastoma is the most common malignant brain tumour in children under the age of four and the second most common in children aged five to fourteen. The median age of diagnosis is seven, with children under the age of ten accounting for more than 70% of all pediatric medulloblastomas diagnosed.

• Medulloblastoma incidence ranges from 1.49 to 3.72 per million population in the USA annually.

Thelansis’s “Medulloblastoma Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Medulloblastoma treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

KOLs insights of Medulloblastoma across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Medulloblastoma Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Medulloblastoma – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032